A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor

Authors

  • Theresa A. Zesiewicz MD,

    Corresponding author
    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA
    4. National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    5. James A. Haley Veterans Administration Hospital, University of South Florida, Tampa, Florida, USA
    • University of South Florida, 12901 Bruce B. Downs Blvd, MDC Box 55, Tampa, Florida 33612
    Search for more papers by this author
  • Christopher L. Ward LMT,

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Robert A. Hauser MD,

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. Department of Pharmacology and Experimental Therapeutics, University of South Florida, Tampa, Florida, USA
    4. National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Jason L. Salemi MPH,

    1. Birth Defects Surveillance Program, Department of Pediatrics, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Shaila Siraj BS,

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Maria-Carmen Wilson MD,

    1. Department of Neurology, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author
  • Kelly L. Sullivan MSPH

    1. Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida, USA
    2. Department of Neurology, University of South Florida, Tampa, Florida, USA
    3. National Parkinson Foundation Center of Excellence, University of South Florida, Tampa, Florida, USA
    Search for more papers by this author

  • The authors have confirmed with the Editor that their work complies with the Journal's Editorial policy on ghost writing [Mov Disord 2005;20(12):1536].

Abstract

We performed a pilot, double-blind, placebo-controlled, randomized trial to evaluate the efficacy and tolerability of pregabalin (PGB, Lyrica), an antiepileptic agent, in treating essential tremor (ET). Twenty two patients with ET were randomly assigned to receive PGB or placebo. PGB was initiated at 50 mg/day and was escalated by 75 mg/day every 4 days to a maximum dose of 600 mg/day. Patients were evaluated by accelerometry and the Fahn–Tolosa–Marin (FTM) rating scale. There was a significant reduction in tremor amplitude in the PGB group compared with the placebo group, as measured by accelerometry, at a mean dose of 286.76 ± 100.05 mg/day. Action tremor limb scores on the FTM also improved in the PGB group compared with the placebo group (P-value for multilevel modeling = 0.04). PGB was fairly well tolerated, with about one-third of patients dropping out of the study because of adverse events. PGB provided significant improvements in accelerometry and in action tremor limb scores on the FTM. However, larger studies are needed to further evaluate the potential effect of PGB on ET. © 2007 Movement Disorder Society

Ancillary